Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Ductal Carcinoma
Invasive Breast Carcinoma
Invasive Ductal Breast Carcinoma

Interventions

BIOLOGICAL: Talimogene laherparepvec
DRUG: Paclitaxel

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]